You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JAK2

Showing 1 - 25 of 635
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Myelofibrosis Trial in Paris (Ruxolotinib)

Completed
  • Myelofibrosis
  • Paris, France
    ROBIN
Jul 26, 2022

Carotid Plaque Burden in Philadelphia Negative

Recruiting
  • Myeloproliferative Neoplasm
    • Sohag, Egypt
      Faculty of Medicine
    Aug 14, 2023

    BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

    Recruiting
    • BCR-JAK2 Fusion Protein Expression
    • +11 more
    • Palo Alto, California
    • +3 more
    Oct 5, 2022

    Myeloproliferative Tumor, Essential Thrombocythemia, JAK2 Mutation Trial in Ottawa (Apixaban 2.5 MG Oral Tablet [ELIQUIS],

    Recruiting
    • Myeloproliferative Neoplasm
    • +5 more
    • Apixaban 2.5 MG Oral Tablet [ELIQUIS]
    • Aspirin 81 mg
    • Ottawa, Ontario, Canada
      The Ottawa Hospital
    Apr 19, 2022

    Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)

    Recruiting
    • Chronic Hand Dermatitis
    • Rochester, New York
      UR Medicine Dermatology College Town
    Aug 9, 2022

    Polycythemia Vera Trial (Givinostat Hydrochloride, Hydroxy Urea)

    Not yet recruiting
    • Polycythemia Vera
    • Givinostat Hydrochloride
    • Hydroxy Urea
    • (no location specified)
    Oct 19, 2023

    Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

    Recruiting
    • Alopecia Areata
    • Janus Kinase 1 and 2
    • Sohag, Egypt
      Sohag University hospitals
    May 12, 2023

    Myelofibrosis, Moderate Thrombocytopenia Trial (Selinexor)

    Not yet recruiting
    • Myelofibrosis
    • Moderate Thrombocytopenia
    • (no location specified)
    Jul 31, 2023

    Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

    Not yet recruiting
    • Severe Aplastic Anemia
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 23, 2023

    Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)

    Not yet recruiting
    • Vitiligo
    • Effect of Drug
    • JAK-2 inhibitor
    • Topical corticosteroid
    • (no location specified)
    Mar 19, 2022

    Arterial Function and Atherosclerosis in Essential

    Completed
    Has Results
    • Atherosclerosis
    • imaging
    • (no location specified)
    Oct 6, 2021

    Arteritis, Giant Cell Trial in Rochester (Baricitinib)

    Completed
    Has Results
    • Arteritis, Giant Cell
    • Rochester, Minnesota
      Mayo Clinic
    Apr 7, 2022

    Metastatic Malignant Tumor in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma Trial in

    Active, not recruiting
    • Metastatic Malignant Neoplasm in the Bone
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Scottsdale, Arizona
      Mayo Clinic in Arizona
    Jan 4, 2023

    Myelofibrosis Trial in Belgium, Netherlands (Pacritinib)

    Active, not recruiting
    • Myelofibrosis
    • Antwerpen, Belgium
    • +11 more
    Aug 19, 2022

    Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)

    Active, not recruiting
    • Chronic Graft vs Host Disease
    • Chronic Graft-Versus-Host Disease
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Nov 29, 2022

    Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

    Recruiting
    • Cicatricial Alopecia
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    Aug 16, 2022

    Lupus Nephritis Trial in Assiut (Anti JAK1,2)

    Active, not recruiting
    • Lupus Nephritis
    • Anti JAK1,2
    • Assiut, Assuit, Egypt
      Manal Hassanien
    Jun 21, 2022

    Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

    Not yet recruiting
    • Diabetes Mellitus, Type 1
    • Abrocitinib 200 MG Oral Tablet
    • +2 more
    • (no location specified)
    Feb 21, 2023

    Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression

    Completed
    • Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
    • JAK expression
    • Mansoura, Egypt
      Mansoura University Hospital
    Dec 9, 2020

    Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

    Recruiting
    • Abatacept
    • +2 more
    • Hangzhou, Zhejiang, China
      Zhejiang Provincial People's Hospital
    Jul 5, 2022

    Idiopathic Inflammatory Myopathies Trial in London (Baricitinib)

    Recruiting
    • Idiopathic Inflammatory Myopathies
    • London, United Kingdom
      King's College Hospital NHS Foundation Trust
    May 19, 2022

    Myeloproliferative Tumor, Splanchnic Vein Thrombosis, JAK2 V617 Trial in London (Drugs, procedures)

    Enrolling by invitation
    • Myeloproliferative Neoplasm
    • +2 more
    • Drugs, procedures
    • London, United Kingdom
      Royal Free London Hospital
    Jul 29, 2021

    Immunoclassification, Psoriasis Trial in Hangzhou (adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors,

    Recruiting
    • Immunoclassification
    • Psoriasis
    • adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
    • Hangzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Aug 16, 2022

    Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

    Recruiting
    • Acute Myeloid Leukemia
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 18, 2022

    Myelomonocytic Leukemia Trial in United States (Ruxolitinib)

    Completed
    Has Results
    • Myelomonocytic Leukemia
    • Tampa, Florida
    • +5 more
    Sep 9, 2022